U.S. markets open in 1 hour 41 minutes
  • S&P Futures

    4,218.50
    +4.75 (+0.11%)
     
  • Dow Futures

    33,773.00
    +12.00 (+0.04%)
     
  • Nasdaq Futures

    14,167.50
    +37.50 (+0.27%)
     
  • Russell 2000 Futures

    2,277.90
    -3.00 (-0.13%)
     
  • Crude Oil

    73.15
    -0.51 (-0.69%)
     
  • Gold

    1,783.70
    +0.80 (+0.04%)
     
  • Silver

    26.02
    -0.00 (-0.02%)
     
  • EUR/USD

    1.1903
    -0.0021 (-0.18%)
     
  • 10-Yr Bond

    1.4840
    0.0000 (0.00%)
     
  • Vix

    17.49
    -3.21 (-15.51%)
     
  • GBP/USD

    1.3902
    -0.0031 (-0.22%)
     
  • USD/JPY

    110.4810
    +0.1830 (+0.17%)
     
  • BTC-USD

    31,485.94
    -806.86 (-2.50%)
     
  • CMC Crypto 200

    750.39
    -99.96 (-11.75%)
     
  • FTSE 100

    7,085.06
    +22.77 (+0.32%)
     
  • Nikkei 225

    28,884.13
    +873.20 (+3.12%)
     

Chinook Therapeutics' BION-1301 Shows Reduction In 24-Hour Proteinuria In Nephropathy Trial

·1 min read
  • Chinook Therapeutics Inc (NASDAQ: KDNY) has announced interim data from the ongoing Phase 1/2 study of BION-1301 in patients with IgA Nephropathy (IgAN).

  • The findings were presented at the 58th European Renal Association – European Dialysis and Transplant Association (ERA-EDTA) Virtual Congress.

  • BION-1301 has demonstrated a clinically meaningful mean reduction in 24-hour proteinuria.

  • The candidate has been well-tolerated, with no treatment-related adverse events, SAEs, infusion-related reactions, or treatment discontinuations due to adverse events.

  • To date, no anti-drug antibodies have been observed in patients.

  • BION-1301 has durably reduced serum IgA and IgM levels and, to some extent, IgG levels.

  • The treatment has also resulted in significant and sustained reductions in Gd-IgA1, demonstrating depletion of the pathogenic IgA variant.

  • Price Action: KDNY shares are up 3.04% at $18.13 during the market session on the last check Tuesday.

See more from Benzinga

© 2021 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.